{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:04:33Z","timestamp":1777957473490,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-03818-7","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T11:11:58Z","timestamp":1737198718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of topical and systemic therapy on carotid-intima media thickness in psoriasis"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-4823","authenticated-orcid":false,"given":"Elif Cansel","family":"Gumus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3310-3217","authenticated-orcid":false,"given":"Ugur","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8269-9139","authenticated-orcid":false,"given":"Selim","family":"Gumus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-1926","authenticated-orcid":false,"given":"Burhan","family":"Engin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"4","key":"3818_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ (2020) Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol 182(4):840\u2013848. https:\/\/doi.org\/10.1111\/bjd.18245","journal-title":"Br J Dermatol"},{"issue":"9","key":"3818_CR2","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jid.2021.02.764","volume":"141","author":"D Yan","year":"2021","unstructured":"Yan D, Gudjonsson JE, Le S et al (2021) New frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. J Invest Dermatol 141(9):2112\u20132122e3. https:\/\/doi.org\/10.1016\/j.jid.2021.02.764","journal-title":"J Invest Dermatol"},{"key":"3818_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3899\/jrheum.190119","volume":"95","author":"DD O\u2019Rielly","year":"2019","unstructured":"O\u2019Rielly DD, Jani M, Rahman P, Elder JT (2019) The Genetics of Psoriasis and Psoriatic Arthritis. J Rheumatol Suppl 95:46\u201350. https:\/\/doi.org\/10.3899\/jrheum.190119","journal-title":"J Rheumatol Suppl"},{"issue":"10","key":"3818_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00011-017-1065-z","volume":"66","author":"M Furue","year":"2017","unstructured":"Furue M, Kadono T (2017) Inflammatory skin march in atopic dermatitis and psoriasis. Inflamm Res 66(10):833\u2013842. https:\/\/doi.org\/10.1007\/s00011-017-1065-z","journal-title":"Inflamm Res"},{"key":"3818_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"5","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH (2018) Systemic \u0131nflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol 5:9:579. https:\/\/doi.org\/10.3389\/fimmu.2018.00579","journal-title":"Front Immunol"},{"key":"3818_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J et al (2017) From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol 76:290\u2013298. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.017","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"3818_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C, Pathophysiology (2020) Clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006","journal-title":"JAMA"},{"issue":"4","key":"3818_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"A Thatiparthi","year":"2021","unstructured":"Thatiparthi A, Martin A, Liu J et al (2021) Biologic Treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol 22(4):425\u2013442. https:\/\/doi.org\/10.1007\/s40257-021-00603-w","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"3818_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2011.06.035","volume":"67","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Szapary P, Mrowietz U et al (2012) Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 67(1):76\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2011.06.035","journal-title":"J Am Acad Dermatol"},{"issue":"10281","key":"3818_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN, Psoriasis (2021) Lancet 397(10281):1301\u20131315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6","journal-title":"Lancet"},{"issue":"6","key":"3818_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/1346-8138.15840","volume":"48","author":"F Yamazaki","year":"2021","unstructured":"Yamazaki F, Psoriasis (2021) Comorbidities. J Dermatol 48(6):732\u2013740. https:\/\/doi.org\/10.1111\/1346-8138.15840","journal-title":"J Dermatol"},{"issue":"1","key":"3818_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/exd.13403","volume":"27","author":"SP Jin","year":"2018","unstructured":"Jin SP, Koh SJ, Yu DA et al (2018) Imiquimod-applied interleukin-10 deficient mice better reflects severe and persistent psoriasis with systemic inflammatory state. Exp Dermatol 27(1):43\u201349. https:\/\/doi.org\/10.1111\/exd.13403","journal-title":"Exp Dermatol"},{"issue":"12","key":"3818_CR13","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2005.03.040","volume":"45","author":"H Methe","year":"2005","unstructured":"Methe H, Brunner S, Wiegand D et al (2005) Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 45(12):1939\u20131945. https:\/\/doi.org\/10.1016\/j.jacc.2005.03.040","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3818_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1161\/STROKEAHA.114.006516","volume":"46","author":"A Abbas","year":"2015","unstructured":"Abbas A, Gregersen I, Holm S et al (2015) Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23\/interleukin 17 axis. Stroke 46(3):793\u2013799. https:\/\/doi.org\/10.1161\/STROKEAHA.114.006516","journal-title":"Stroke"},{"key":"3818_CR15","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fimmu.2018.01234","volume":"9","author":"AP Sajja","year":"2018","unstructured":"Sajja AP, Joshi AA, Teague HL et al (2018) Potential immunological links between psoriasis and cardiovascular disease. Front Immunol 9:1234. https:\/\/doi.org\/10.3389\/fimmu.2018.01234","journal-title":"Front Immunol"},{"issue":"4","key":"3818_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jaad.2013.06.019","volume":"69","author":"H J\u00f3kai","year":"2013","unstructured":"J\u00f3kai H, Szakonyi J, Kont\u00e1r O et al (2013) Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol 69(4):523\u2013529. https:\/\/doi.org\/10.1016\/j.jaad.2013.06.019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3818_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.55563\/clinexprheumatol\/3qiqk3","volume":"39","author":"A Ortolan","year":"2021","unstructured":"Ortolan A, Ramonda R, Lorenzin M et al (2021) Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. Clin Exp Rheumatol 39(1):158\u2013161. https:\/\/doi.org\/10.55563\/clinexprheumatol\/3qiqk3","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"3818_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/138161282004140213123852","volume":"20","author":"EA Brezinski","year":"2014","unstructured":"Brezinski EA, Follansbee MR, Armstrong EJ et al (2014) Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20(4):513\u2013528. https:\/\/doi.org\/10.2174\/138161282004140213123852","journal-title":"Curr Pharm Des"},{"issue":"2","key":"3818_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/biomedicines11020318","volume":"11","author":"A Tsiogka","year":"2023","unstructured":"Tsiogka A, Gregoriou S, Stratigos A et al (2023) The \u0131mpact of treatment with IL-17\/IL-23 \u0131nhibitors on subclinical atherosclerosis in patients with plaque psoriasis and\/or psoriatic arthritis: a systematic review. Biomedicines 11(2):318. https:\/\/doi.org\/10.3390\/biomedicines11020318","journal-title":"Biomedicines"},{"issue":"4","key":"3818_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Dey AK, Goyal A et al (2019) Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 115(4):721\u2013728. https:\/\/doi.org\/10.1093\/cvr\/cvz009","journal-title":"Cardiovasc Res"},{"issue":"9","key":"3818_CR21","doi-asserted-by":"publisher","first-page":"e011199","DOI":"10.1161\/CIRCIMAGING.120.011199","volume":"13","author":"H Choi","year":"2020","unstructured":"Choi H, Uceda DE, Dey AK et al (2020) Treatment of Psoriasis with Biologic Therapy is Associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study. Circ Cardiovasc Imaging 13(9):e011199. https:\/\/doi.org\/10.1161\/CIRCIMAGING.120.011199","journal-title":"Circ Cardiovasc Imaging"},{"key":"3818_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cjca.2019.06.021","volume":"36","author":"G Makavos","year":"2020","unstructured":"Makavos G, Ikonomidis I, Andreadou I et al (2020) Effects of Interleukin 17A inhibition on myocardial deformation and vascular function in Psoriasis. Can J Cardiol 36:100\u2013111. https:\/\/doi.org\/10.1016\/j.cjca.2019.06.021","journal-title":"Can J Cardiol"},{"key":"3818_CR23","doi-asserted-by":"publisher","unstructured":"Piros \u00c9A, Szab\u00f3 \u00c1, Rencz F et al (2021) Impact of Interleukin-17 inhibitor therapy on arterial intima-media thickness among severe psoriatic patients life. 11:919. https:\/\/doi.org\/10.3390\/life11090919","DOI":"10.3390\/life11090919"},{"key":"3818_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/ced.14180","volume":"45","author":"M Marovt","year":"2020","unstructured":"Marovt M, Marko PB, Pirnat M et al (2020) Effect of biologics targeting interleukin-23\/-17 axis on subclinical atherosclerosis: results of a pilot study. Clin Exp Dermatol 45:560\u2013564. https:\/\/doi.org\/10.1111\/ced.14180","journal-title":"Clin Exp Dermatol"},{"key":"3818_CR25","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Duffin KC et al (2020) A randomized placebo-controlled trial of Secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Investig Dermatol 140:1784\u20131793. https:\/\/doi.org\/10.1016\/j.jid.2020.01.025","journal-title":"J Investig Dermatol"},{"key":"3818_CR26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1365-2133.2011.10257.x","volume":"164","author":"K Reich","year":"2011","unstructured":"Reich K, Langley RG, Lebwohl M et al (2011) Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 164:862\u2013872. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10257.x","journal-title":"Br J Dermatol"},{"issue":"4","key":"3818_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jdv.16018","volume":"34","author":"W Rungapiromnan","year":"2020","unstructured":"Rungapiromnan W, Mason KJ, Lunt M et al (2020) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol 34(4):769\u2013778. https:\/\/doi.org\/10.1111\/jdv.16018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3818_CR28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","volume":"176","author":"W Rungapiromnan","year":"2017","unstructured":"Rungapiromnan W, Yiu ZZN, Warren RB et al (2017) Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 176(4):890\u2013901. https:\/\/doi.org\/10.1111\/bjd.14964","journal-title":"Br J Dermatol"},{"key":"3818_CR29","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/jdv.15653","volume":"33","author":"JJ Crowley","year":"2019","unstructured":"Crowley JJ, Warren RB, Cather JC (2019) Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol 33:1676\u20131684. https:\/\/doi.org\/10.1111\/jdv.15653","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3818_CR30","doi-asserted-by":"publisher","first-page":"e2022011","DOI":"10.5826\/dpc.1201a11","volume":"12","author":"A Dattola","year":"2022","unstructured":"Dattola A, Manenti G, Ferrari D et al (2022) Prevalence of atherosclerosis in psoriatic patients detected with Epiaortic Color Doppler Ultrasound and Computed Tomography Angiography. Dermatol Pract Concept 12(1):e2022011. https:\/\/doi.org\/10.5826\/dpc.1201a11","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"3818_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaad.2018.03.046","volume":"79","author":"JM Gelfand","year":"2018","unstructured":"Gelfand JM, Commentary (2018) Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?A critical question that we are only just beginning to answer. J Am Acad Dermatol 79(1):69\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.046","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3818_CR32","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/jcm12031162","volume":"12","author":"H Terui","year":"2023","unstructured":"Terui H, Asano Y (2023) Biologics for reducing cardiovascular risk in psoriasis patients. J Clin Med 12(3):1162. https:\/\/doi.org\/10.3390\/jcm12031162","journal-title":"J Clin Med"},{"issue":"10","key":"3818_CR33","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.adengl.2012.02.004","volume":"103","author":"L Puig","year":"2012","unstructured":"Puig L (2012) Cardiovascular risk and psoriasis: the role of biologic therapy. Actas Dermosifiliogr 103(10):853\u2013862. https:\/\/doi.org\/10.1016\/j.adengl.2012.02.004","journal-title":"Actas Dermosifiliogr"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03818-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T11:11:59Z","timestamp":1737198719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03818-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3818"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03818-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}